Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M.H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan Manuel Sancho, Ana Jimenez-Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. ParkJames J. Wu, Ana Nunes, John Reitan, Sally W. Wade, Gilles Salles

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma'. Together they form a unique fingerprint.

Medicine and Dentistry